Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...

InTandem Capital Partners ("InTandem Capital" or the "Firm"), a healthcare services-focused private equity firm, announced today that it has partnered with the founder and management team at Clinilabs ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

The global stem cell therapy market is poised for remarkable growth, with revenues projected to escalate from USD 394.50 million in 2024 to USD 2,612.92 million by 2033, reflecting a compelling ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...

JERUSALEM, March 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha ...

and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safe ...

This has largely been driven by regulation, with national regulators such as FDA and PMDA mandating the use of submission standards such as SEND, SDTM, and ADaM. This post shines a spotlight on ...

The Pharmaceuticals and Medical Device Agency (PMDA) offers consultation before clinical trial notification (CTN) submission, to ensure that it meets scientific, data collection, analytical ...